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Viewpoint
Progress in cystic fibrosis (CF) over the past few decades has been nothing short of miraculous on several fronts: median survival in the United 
States has increased from 15 years in 1975 to 41 years 
in 2013, with predictions into the 50s for children born 
this century.1 Our understanding of the genetic and 
cellular underpinnings of CF have similarly grown 
exponentially, beginning in the 1980s with the identi-
fication of the cellular ion transport defect2 and the 
discovery of the gene, dubbed CFTR (cystic fibrosis 
transmembrane conductance regulator).3 Now in the 
past 3 years, with the advent of mutation-specific 
therapies, we have entered a new era that promises 
even greater improvement in the quality and the 
length of lives. 
The first of these small molecule therapies to 
come to fruition (and to market) was Vertex 
Pharmaceuticals’ (Boston, Massachusetts) ivacaftor 
(sold as Kalydeco), which received FDA approval in 
2012. In a clinical trial, ivacaftor brought about dra-
matic improvements in pulmonary function and body 
weight as well as crucial confirmation of a CFTR cel-
lular effect, reduced elevated sweat chloride concen-
trations—for centuries the hallmark of the disease—
to near normal levels.4 That’s the good news. The bad 
news is that (1) this compound is effective for only a 
few patients with CF, specifically those (less than 
10%) whose CFTR gene mutations translate into a 
defective protein that is transported successfully 
through the cytoplasm to insert into the plasma (cell) 
membrane but fails to gate (open for; ie, conduct) chlo-
ride and bicarbonate normally and (2) the drug is phe-
nomenally expensive ($311 000/y wholesale from 
Vertex, $376 000/y through a specialty pharmacy). 
And very recently, another drug, actually a combina-
tion of ivacaftor and another compound known as 
lumacaftor, appears to have a statistically significant 
but limited effect for many of the remaining patients, 
specifically those who are homozygous for the F508del 
mutation, ie, some 50% of all US patients. In this 
mutation, the CFTR protein starts to be made in the 
cytoplasm, but very little survives the journey from 
the cytoplasm (endoplasmic reticulum) to the plasma 
(cell) membrane, and the small amount that does com-
plete the trip still functions only very poorly; thus 
defective proteins from this mutation need help to get 
to their destination in the cell membrane. Lumacaftor 
provides the ride, but then the protein still needs help 
to open properly and ivacaftor provides the slide. This 
combination drug was approved by the US Food and 
Drug Administration (FDA) this year and is marketed 
as Orkambi, also made by Vertex. In Phase 3 trials, the 
combination appeared to lengthen significantly the 
time between pulmonary infections that require intra-
venous antibiotic treatment and to improve pulmo-
nary function.5 That’s the good news. However, the 
magnitude of the pulmonary function improvement, 
at some 3%, is much smaller than that seen with iva-
caftor alone in patients with the G551D mutation (the 
most common of the gating mutations) and, although 
statistically significant, is of marginal clinical benefit. 
Further, there is some evidence that the 2 components 
of the combination drug do not work well together, 
with 1 interfering with the function of the other.6 
Despite these limitations, but perhaps predictably, the 
price of the drug is an astounding $259 000 per year 
from Vertex, and either $286 892.40 from one of the 
specialty pharmacies that supply the drug to patients, 
or, if one is willing to do aggressive comparison shop-
ping, it can be purchased for $286 890.24 per year from 
another specialty pharmacy, for an annual savings of 
$2.16! It is surely intriguing that the combination of 
ivacaftor and lumacaftor—Orkambi—is actually 
about $50 000 per year cheaper than ivacaftor alone 
and even more intriguing since there is more ivacaftor 
in Orkambi than in Kalydeco per dose. Perhaps like 
Jack Nicholson’s character in Five Easy Pieces, who, 
when told he can’t have a side order of toast, orders a 
chicken salad sandwich on toast and tells the waitress 
to “hold the chicken,” patients with G551D should 
order lumacaftor-ivacaftor, but suggest “hold the 
lumacaftor” or just have the whole sandwich.
How did we get here? Prior to the discovery of the 
cellular defect and the CF gene and even since, our 
treatments have not been directed toward the basic 
defect but rather toward “downstream effects”: tedious 
chest physical therapy to clear thick mucus from bron-
chi, antibiotics to treat bronchial infection caused by 
the infection-prone endobronchial milieu, pancreatic 
enzymes to replace those blocked by mucus-clogged 
pancreatic ducts. Things changed about 15 years ago, 
when the Cystic Fibrosis Foundation, a voluntary 
health organization founded in 1955 by parents frus-
trated by their children’s horrendous quality and piti-
ably short length of life and continually supported over 
the ensuing 60 years by funds raised by CF families and 
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their friends, took an unprecedented and risky step: it 
invested some $75 million in Aurora Biosciences Corp, 
Cambridge, Massachusetts, a small biotech company, 
to encourage it to find a drug that would correct the 
basic cellular defect causing CF. Then, Vertex bought 
Aurora and continued the work, based on the science 
that had been developed by universities and Aurora 
and paid for by public funds (National Institures of 
Health grants) and charitable donations. Finally, the 
work paid off—in scientific, clinical, and financial 
terms—with the licensing of Kalydeco. Vertex officials 
justify the sky-high price by pointing to the additional 
funds they supplied for research and development, the 
magnitude of the benefit to patients, and the small 
number of patients who qualify to use the drug (there 
are roughly 1200 patients in the United States with the 
G551D mutation and a smaller number who now 
qualify with mutations that cause related defects). 
Some observers, ourselves included,7 have attrib-
uted the price to the age-old price-setting standard in 
capitalism: “What the market will bear.” So far in the 
United States, the market (private insurers and state 
health programs) has borne the price of Kalydeco with 
hardly a squeak.8 Vertex executives have also pointed 
to their need to make the company profitable to satisfy 
their investors and have raised the specter of Vertex 
being bought out by a larger company less committed 
to developing new CF therapeutics. While not ques-
tioning their sincerity, some have been appalled by the 
windfall multimillion-dollar compensation packages 
the executive officers have managed for themselves,9 
raising eyebrows and ire over the huge prices for drugs 
that were developed through the work and sacrifice of 
patients and families, based substantially on science 
done with public funding and supported by the CF 
Foundation. The issue is complicated by the hundreds 
of millions of dollars coming back to the CFF in royal-
ties from the sales of Kalydeco10 and the $3.3 billion 
the foundation reaped from the sale of future royalties 
from this and other potential drugs.11 The complica-
tion is the push-pull between the foundation’s roles in 
advocating for patients (eg, need for affordable prices 
for CF drugs) and in securing funds for new research, 
better clinical care, and new drugs (need for more 
money from all sources, including royalties from drug 
sales). Opinions differ on how well the CFF has been 
and will be able to navigate these tricky shoals.
The problem of exceedingly high drug prices goes 
beyond CF. We have seen high prices for drugs target-
ing other conditions, including hepatitis C and various 
cancers. In 2014, all new FDA-approved cancer drugs 
were priced above $120 000 per year of use,12 more than 
twice the average annual household gross income in 
the United States (which is about $52 000). (And, per-
haps taking a page from Vertex and others, even manu-
facturers of inexpensive tried-and-true drugs are get-
ting into the act: doxycycline, an antibiotic used for 
decades in CF, went from $20 a bottle in October 2013 
to $1849 by April 2014.) Some doctors and hospitals 
have successfully pushed back. When Sanofi (Paris, 
France) introduced the colon cancer drug Zaltrap at 
about $11 000 a month, the staff at Memorial Sloan-
Kettering Cancer Center in New York declined to stock 
the drug, pointing out that a drug already on their for-
mulary was half the price and equally effective. Almost 
immediately, Sanofi cut the price of Zaltrap in half.13 A 
recent commentary by more than 100 cancer special-
ists condemns the unconscionable prices for cancer 
drugs and the disconnect between drug costs and aver-
age patients’ means and calls for a nationwide petition 
of protest.12 These specialists hope to collect 1 million 
signatures, which will make their case heard and acted 
on. Perhaps they will succeed.
In CF, the situation is different. While there are 
millions of cancer patients, most of whom are old 
enough to vote, there are but 30 000 patients with CF 
in the country, and half are children. And unlike the 
situation with Sanofi’s Zaltrap where there was com-
petition, to date, there are no drugs competing with 
Vertex’s Kalydeco and Orkambi. Although some com-
panies are working on developing such drugs, for the 
time being, competitive pressures are absent. What 
about government intervention? Prices for drugs are 
dramatically more expensive in the United States than 
in any other developed country, largely because other 
countries have either a single (government) payer or 
regulations that cap prices. In the current political cli-
mate in the United States, this seems unlikely. The 
2003 Medicare Prescription Drug, Improvement and 
Modernization Act, which established a prescription 
drug program for Medicare, expressly prohibited 
Medicare from negotiating drug prices with pharma-
ceutical companies, and attempts to rescind this legis-
lation have been unsuccessful. The pharmaceutical 
industry pumps hundreds of millions of dollars each 
year into lobbying Congress and supporting congres-
sional candidates. 
To date, few if any patients in the United States 
have been unable to obtain their Kalydeco because 
either their insurance (private or state) covered it or 
Vertex’s patient assistance program has helped with 
copays. It is too early to say if insurance companies 
and state programs will be as willing to cover the simi-
larly high cost of Orkambi for some 10 times as many 
patients. If they do not, perhaps the uproar from 
patients and physicians will move regulators or Vertex 
to reconsider their pricing structure.
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